Biotech Stocks See Fresh Catalysts: Tempest, DataMEDS, NeurAxis & MAIA

Biotech stocks drew attention following multiple company-specific updates: Tempest Therapeutics announced a new in vivo CAR-T licensing agreement, while DataMEDS AI acquired Helomics. NeurAxis expanded coverage for its PENFS therapy, and MAIA Biotechnology reported an initial U.S. patient-related milestone, though the provided article text does not specify further details. The updates are broadly constructive for the named companies but are unlikely to have broad market impact.